$NSPR news, NSPR 0.528 0.00 0.00 136,170 0.67 0.6701
InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS
1 hour 21 minutes ago - DJNF
InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS
TEL AVIV, ISRAEL--(Marketwired - May 30, 2017) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"
, a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the first two patients in Hong Kong have been successfully treated with CGuard(TM) EPS. The two cases were conducted on patients with carotid artery stenosis at St. Teresa Hospital by Dr. PW Cheng and Dr. YW Chow, a leading neurointerventional radiologist and leading cardiologist, respectively.
These first cases in Hong Kong follow the previously announced distribution agreement for CGuard(TM) EPS with a distribution partner in Hong Kong that was announced two months ago. These are the first cases performed in the Asia Pacific region and represent a further milestone for InspireMD's global expansion strategy.
Dr. PW Cheng and Dr. YW Chow commented, "These procedures went seamlessly and we are very pleased with the way CGuard performed. We are very excited to have access to this innovative technology as it provides vastly superior safety to carotid artery stenting (CAS) patients compared to conventional stents. We envision this procedure becoming the standard of care for carotid stenting procedures."
Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We are pleased to report another milestone in the continued execution of our growth strategy in the Asia Pacific region. Dr. Cheng and Dr. Chow are among the top physicians in Hong Kong in their respective fields, further illustrating our ability to attract the top key opinion leaders around the world. We look forward to announcing further progress in the Asia Pacific region over the coming months."
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet(TM) technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard(TM)), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants are quoted on the NYSE MKT under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans, " "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
InspireMD, Inc.
Craig Shore
Chief Financial Officer
Phone: 1-888-776-6804 FREE
Email: craigs@inspiremd.com
Crescendo Communications, LLC
David Waldman
Phone: (212) 671-1021
Email: NSPR@crescendo-ir.com
(MORE TO FOLLOW) Dow Jones Newswires
May 30, 2017 07:00 ET (11:00
InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS
1 hour 21 minutes ago - DJNF
InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard EPS
TEL AVIV, ISRAEL--(Marketwired - May 30, 2017) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"
, a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the first two patients in Hong Kong have been successfully treated with CGuard(TM) EPS. The two cases were conducted on patients with carotid artery stenosis at St. Teresa Hospital by Dr. PW Cheng and Dr. YW Chow, a leading neurointerventional radiologist and leading cardiologist, respectively. These first cases in Hong Kong follow the previously announced distribution agreement for CGuard(TM) EPS with a distribution partner in Hong Kong that was announced two months ago. These are the first cases performed in the Asia Pacific region and represent a further milestone for InspireMD's global expansion strategy.
Dr. PW Cheng and Dr. YW Chow commented, "These procedures went seamlessly and we are very pleased with the way CGuard performed. We are very excited to have access to this innovative technology as it provides vastly superior safety to carotid artery stenting (CAS) patients compared to conventional stents. We envision this procedure becoming the standard of care for carotid stenting procedures."
Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We are pleased to report another milestone in the continued execution of our growth strategy in the Asia Pacific region. Dr. Cheng and Dr. Chow are among the top physicians in Hong Kong in their respective fields, further illustrating our ability to attract the top key opinion leaders around the world. We look forward to announcing further progress in the Asia Pacific region over the coming months."
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet(TM) technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard(TM)), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants are quoted on the NYSE MKT under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans, " "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
InspireMD, Inc.
Craig Shore
Chief Financial Officer
Phone: 1-888-776-6804 FREE
Email: craigs@inspiremd.com
Crescendo Communications, LLC
David Waldman
Phone: (212) 671-1021
Email: NSPR@crescendo-ir.com
(MORE TO FOLLOW) Dow Jones Newswires
May 30, 2017 07:00 ET (11:00
2
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
